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Fat malabsorption in pancreatic insufficient cystic fibrosis (CF) patients is classically treated with pancreatic enzyme replacement therapy (PERT).
Despite PERT, intestinal fat absorption remains insufficient in most CF patients. Several factors have been suggested to contribute to the persistent fat
malabsorption inCF (CFPFM).We reviewed the current insights concerning the proposed causes of CFPFMand the corresponding intervention studies.
Most data are obtained from studies in CF patients and CF mice. Based on the reviewed literature, we conclude that alterations in intestinal pH and
intestinal mucosal abnormalities are most likely to contribute to CFPFM. The presently available data indicate that acid suppressive drugs and broad
spectrum antibiotics could be helpful in individual CF patients for optimizing fat absorption and/or nutritional status.
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Most patients with cystic fibrosis (CF) have a suboptimal
nutritional status. In order to minimize morbidity and mortality,
obtaining and maintaining a good nutritional status remain one
of the important challenges in CF [1–3]. Next to preventing and
controlling pulmonary infections, a high dietary energy intake
diet combined with pancreatic enzyme replacement therapy
(PERT) is a classic cornerstone in CF care.
Despite optimizing and maximizing PERT, fat malabsorp-
tion in most CF patients persists (CFPFM). Rather than the
physiological absorption above 95%, most CF patients show a
decreased intestinal fat absorption of ±85–90% of dietary fat
intake [4,5]. It is reasonable to assume that at least part of the
failure to approach a physiological degree of fat absorption
could still be attributed to inefficiency and inaccurate dosing of
PERT. Also, a non-synchronous entrance of PERT with dietary
energy intake into the duodenum may play a role in CFPFM [6].
However, besides PERT related issues, other factors have been
implied to be involved in CFPFM [7,8].
During the last decades, several of these potential contributing
factors to CFPFMhave been addressed and investigated in patient
studies as well as in animal studies. In this review, wewill provide
an overview of the different mechanisms that have been implied
to contribute to CFPFM and describe the results of corresponding
interventional studies on fat absorption and/or nutritional status.
We will mainly describe studies performed in CF patients and CF
mice. CF mice are especially suitable to exclusively investigate
CFPFM, as most CF mouse models do not suffer from pancreatic
insufficiency but do exhibit impaired absorption of fat [9]. Based
on the reviewed literature, we will conclude our review with
clinical implications and suggestions for further research.
In order to fully recognize and understand the CF-related
factors that might be involved in CFPFM, we start to describe
the physiological process of fat digestion and absorption.2. Physiology of fat digestion and absorption
Dietary fat intakemainly consists of long-, medium- and short-
chain triglycerides. Themechanism of digestion and absorption of
these lipids can be dissected into several sequential steps. In
contrast to long-chain triglycerides, medium- and short-chain
triglycerides are known to circumvent several steps in lipiddigestion and absorption. For example, unlike long-chain
triglycerides, medium- and short chain triglycerides are less
dependent upon solubilization, escape the re-esterification into
triglycerides and are directly absorbed into the portal system
without being assembled into chylomicrons [10]. Since the
majority of dietary fat and energy intake consists of long-chain
triglycerides (92–96%), we exclusively focused on their
mechanism of intestinal digestion and absorption. The mecha-
nism of digestion and absorption of long-chain triglycerides can
be dissected into several sequential processes (Fig. 1A).
2.1. Emulsification
Emulsification of triglycerides is a process in which (water-
insoluble) fat droplets are suspended in an aqueous environ-
ment. Emulsification can be achieved by mechanical as well as
chemical means. Mechanical emulsification is attained by
chewing and forcing dietary fat with high pressure through a
small opening (e.g. the pylorus) and dispersing large fat droplets
into smaller droplets. Chemical emulsification is attained by the
action of bile and prevents the emulsion from re-coalescing.
Emulsification results in a fine, relatively stable oil-in-water
emulsion with an increased surface area. The water soluble
digestive/lipolytic enzymes are active at the site of the water–oil
interface.
2.2. Lipolysis
During lipolysis, the breakdown (hydrolysis) of lipids into
smaller particles is continued. Around 10–30% of the
triglycerides are hydrolyzed in the stomach into diglycerides
and free fatty acids, catalyzed by lingual and gastric lipase (a
process also known as biochemical/lipolytic emulsification
[10]). Under physiological conditions, pancreatic lipase com-
pletes the process in the proximal part of the small intestine, by
hydrolyzing the remaining triglycerides and diglycerides into
monoglycerides and free fatty acid molecules. Bile salts are
amphipathic molecules, i.e. they possess a hydrophilic and a
hydrophobic site. Upon exposure to a dietary lipid emulsion at
the level of the proximal small intestine, the hydrophobic site
orients itself towards the hydrophobic lipid droplets, whereas
their hydrophilic site exposes itself to the aqueous (water)
phase. Lipid droplets whose surface is thus covered with bile
Fig. 1. Simplified scheme of fat digestion and absorption in health and in CF conditions. A) Simplified representation of the process of long-chain triglyceride
digestion and absorption in health as described in the text. B) Overview of the various steps in fat digestion and absorption in relation to findings in CF patients and CF
mice. +; disturbed, −; not disturbed, +/−; likely to be disturbed. ND: not determined. References are described in the text.
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allows the anchoring of the pancreas lipase to the oil–water
interface and is essential for lipolytic activity. Under physio-
logical conditions, pancreatic lipase is present in vast excess.
Thus, in CF, fat maldigestion only occurs during severe
pancreatic malfunction [11]. During exocrine pancreatic
insufficiency when pancreatic lipase is severely reduced,
lipolysis is more dependent upon the activity of lingual and
gastric lipase. In CF conditions, lingual lipase remains fully
active in the intestine, where it accounts for more than 90% of
lipase activity, even when the intestinal pH drops below the
optimal level for bile salt dependent lipolysis [12].
2.3. Solubilization
The process in which fat molecules are dissolved in water in
the form of (mixed) micelles is called solubilization. Solubili-
zation enhances the aqueous solubility of fatty acids by several
orders of magnitude (100 to 1000 fold) [10]. Solubilization isnecessary for monoglycerides and free fatty acids to efficiently
overcome the diffusion barrier of the so called unstirred water
layer of the enterocytes [10]. The unstirred water layer separates
the enterocytes from the luminal contents of the intestine.
Solubilization is achieved by the formation of mixed micelles;
mainly consisting of phospholipids and bile salts derived from
biliary secretion. The diameter of the lipid droplets ranges from
100 to 1000 nm, whereas that of mixed micelles ranges from 3
to 5 nm. The hydrophobic part of the lipid molecules, such as
the acyl-chains, will be oriented inwards, whereas the
hydrophilic parts, (such as the carboxylic headgroups) orient
towards the aqueous outside of the micelle. Saturated fatty acids
are more dependent on solubilization than unsaturated fatty
acids, due to the higher hydrophobicity of the former. The
difference in bile salt dependency can be derived from
absorption studies in rats with chronic bile diversion: in such
an intestinal bile deficient condition, absorption of saturated
fatty acids is below 30% of the ingested amount, while the
absorption of unsaturated fatty acids is relatively maintained
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formation is also pH sensitive. Low intestinal pH levels can
severely inhibit micelle formation or induce premature release
of lipolytic products out of micelles [10].2.4. Translocation
Once the mixed micelles diffuse through the unstirred water
layer and arrive at the proximity of the (apical) enterocyte
membrane, the free fatty acids and monoglycerides dissociate
from the micelles. It has been postulated that the acidic
microclimate near the apical membrane of intestinal mucosal
cells, induces micelle-disintegration and favors the transloca-
tion of fatty acid molecules across the enterocyte membrane
[10]. It has remained unclear whether intestinal membrane
transporters are essential for the translocation of fatty acids and
monoglycerides. It is suggested that free fatty acid uptake is
concentration-dependent, in which a high intra-luminal con-
centration drives passive diffusion. Two putative intestinal
transporters have been proposed to be involved fatty acid
uptake; the fatty acid binding protein (FABP) and the fatty acid
translocase/cluster determinant 36 (FAT/CD36) [14]. However,
both transporters are not likely to be involved in fatty acid
uptake into the enterocytes. FABP is only expressed in a small
area of the crypt-villus of the intestine and knockout mice for
FABP and CD36 do not exhibit impairments in fatty acid uptake
[15–17].2.5. Intracellular processing
After being absorbed into the enterocytes, the lipolytic
products migrate to the endoplasmic reticulum, possibly
mediated via the fatty acid binding proteins [14,15]. At the
cytoplasmic surface of the endoplasmic reticulum, the fatty
acids and monoglycerides are re-esterified into triglycerides.
Under physiological conditions, re-esterification mainly occurs
via the monoacylglycerol pathway, i.e. the sequential acylation
of monoacylglycerol by acyl-CoA [10].2.6. Chylomicron production
Newly synthesized triglycerides are transferred into the
smooth endoplasmic reticulum and are assembled into lipopro-
tein particles called chylomicrons. Intestinal phospholipids are
required for chylomicron production in order to prevent
accumulation in the enterocyte [18,19]. Maturation of chylo-
microns (i.e. assembly of fat particles with a phospholipid–
cholesterol–apolipoprotein surface) takes place in the Golgi
apparatus. Chylomicron formation is followed by exocytosis via
the secretory pathway at the basolateral surface of the
enterocyte. The chylomicrons are released into the circulation
via the mesenteric lymph system, via the thoracic duct into the
venous system, after which their contents are systemically
delivered.3. Factors proposed to be associated with persistent fat
malabsorption in CF (CFPFM)
Several factors have been proposed to contribute to CFPFM.
For each of these factors we will describe; (1) how these factors
are affected in CF conditions; (2) what is known about the
relation of these factors with CFPFM; and, (3) what the result of
intervention studies is in CF patients and CF mice when
improving or altering these factors.
3.1. Intestinal pH
3.1.1. CF conditions
CFTR dysfunction reduces pancreatic and duodenal bicar-
bonate secretion [20,21]. Gastric bicarbonate secretion in CF
patients is not affected [22]. Hence, the duodenal pH is (on
average) 1–2 units lower in CF patients compared with healthy
controls. Also, CF patients have significantly longer periods
(postprandial) in which the duodenal pH drops below 4 [23].
The pH values in jejunal and ileal contents from CF patients
vary from lower to similar pH values compared with healthy
controls [23]. CFTR™1Cam knockout mice have adequate
pancreatic bicarbonate secretion, but probably do have reduced
secretions of duodenal bicarbonate [9]. This might explain the
observation in CFTR™1Unc knockout mice, where duodenal pH
is only minimally reduced (~0.25) [21].
3.1.2. Relation with CFPFM
A normal intestinal pH is essential for adequate digestion and
absorption of fat [10]. Recently, Quinton et al. showed that
adequate bicarbonate secretion is essential for mucin expansion
in the intestine [24,25]. When mucin expansion is disturbed by
inadequate release of bicarbonate in CF conditions, viscous and
sticky mucus might impair translocation of lipids to the
enterocyte. A strong relation has been described between
postprandial duodenal pH levels and the degree of fat
malabsorption in CF patients treated with pancreatic enzymes
[26]. These data indicate that interventions to increase intestinal
pH values might improve CFPFM.
3.1.3. Intervention studies
Two double-blind crossover studies evaluated fat absorption
in pediatric and adult CF patients after the addition of
bicarbonate to enteric coated pancreatic enzymes. In the first
study, the average fat absorption increased from 75% to 82% of
the ingested amount [27]. In this study, a beneficial effect on fat
absorption was observed in 75% of the patients. In the second
study, the average fat absorption did not increase, but 50% of
the patients did show an improvement in fat absorption (N5%)
after bicarbonate supplementation [28]. Due to the overall
minimal observed changes in fat absorption, pancreatic
enzymes buffered with bicarbonate are not implemented in
CF care.
In a systematic review, Jones A. evaluated the effect of acid
suppressant therapy on fat absorption and/or fecal fat excretion
and nutritional status [29]. While multiple studies reported
improved fat absorption or reduced fecal fat excretion after acid
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Improved fat absorption was not accompanied with an
improvement in nutritional status. The performed studies
showed high variability in the used dosage of pancreatic
enzymes, choice of acidic suppressive medication and differed
in the inclusion criteria for the degree of fat malabsorption. Due
to these large inter-study differences, it remains difficult to draw
an overall definite conclusion about the effectiveness of acid
suppressive drugs. Evaluating individual data in these inter-
vention studies, a subgroup of patients clearly showed improved
fat absorption. The results indicate that some CF patients do
benefit from acid suppressive therapy. Why some patients
respond, but others show no improvement in fat absorption,
illustrates that an altered pH is not the only factor responsible
CFPFM. Next to this, it is known that acid suppressive drugs
can induce small intestinal bacterial overgrowth (SIBO) and can
alter bile salt metabolism, with a potentially negative effect on
fat absorption [30]. Therefore, acid suppressive therapy should
be imposed with caution, especially in CF patients who are
relatively more prone to SIBO. A trial of proton pump inhibitors
might be useful to evaluate its effectiveness in the individual CF
patient.
Bijvelds et al. investigated the effect of the acidic
suppressive drug omeprazole on lipolysis and uptake of
lipolytic products in CFTR™1CAM knockout mice by using
radio-isotope labeled triglycerides and fatty acids. The
researchers showed that lipolytic activity and lipid absorption
improved after omeprazole treatment [9]. It is likely that
increasing the intestinal pH has a general positive effect on
intestinal fat absorption, since lipolytic and post-lipolytic
activity also partially improved in the omeprazole treated wild
type mice [9].
3.2. Intra-luminal bile salts
3.2.1. CF conditions
CF patients have an increased loss of fecal bile salts [31,32].
It is speculated that the loss of bile salts is due to impaired bile
salt uptake by intestinal mucosal alterations; like thickening of
the mucus barrier and/or SIBO [33]. Because the biosynthesis of
taurine is limited in humans, the fecal loss of bile salts induces
an increased glycine/taurine ratio of conjugated bile salts in CF
patients [34]. In addition, CF patients have an altered bile salt
composition in gallbladder bile. Due to a quantitative increase
in biliary cholate, the percent contribution of cholate is higher,
and the percent contribution of chenodeoxycholate and
deoxycholate is lower in the bile of CF patients [35].
3.2.2. Relation with CFPFM
It has been proposed that excessive fecal loss of bile salts
diminishes the bile salt pool in CF patients and consequently
impairs fat absorption by reducing the solubilization capacity of
bile [31]. However, a subsequent study indicated that the
amount of fecal bile salt excretion was not related to the degree
of fat malabsorption in CF patients [32]. Strandvik et al. showed
that adult CF patients have normal to large bile salt pool sizes
and similar amounts of duodenal bile salts as healthy controls[35]. Bile salt synthesis was normal or even increased,
indicating that CF patients adequately compensate for the
fecal bile salt loss. We confirmed in CF mouse models that fecal
loss of bile salts does not influence the absorption of fat [9].
Homozygous ΔF508 mice and CFTR™1CAM knockout mice
both exhibit, to the same extent, an increased fecal loss of bile
salts, but only the CFTR™1CAM knockout mice had fat
malabsorption [9]. In conclusion, bile salt malabsorption in
itself, at the levels observed in CF patients and CF mice, does
not seem to contribute to CFPFM.
Theoretically, the increased glycine/taurine ratio may impair
fat absorption in an acidic intestinal lumen. Due to the higher
pKa of glycine, glycine conjugated bile salts are less able to
remain in micellar solution [36]. In addition, part of the
glycoconjugates is passively absorbed in the in the proximal
part of the intestine and is, in comparison to tauroconjugates,
less resistant to bacterial degradation [37,38].
Deoxycholate and chenodeoxycholate are relatively hydro-
phobic in comparison to other bile salts. Therefore, a reduction
in these bile salts may theoretically impair fat absorption by
diminishing the solubilization capacity of bile. In general, the
percent contribution, and not the quantitative amount, of
deoxycholate and of chenodeoxycholate is diminished in CF
patients. Thus, the altered bile salt composition is not likely to
contribute to CFPFM. This hypothesis is supported by the fact
that both homozygous ΔF508 mice and CFTR™1CAM
knockout mice show these alterations, while only the CFTR™1-
CAM knockout mice exhibit fat malabsorption [9].
3.2.3. Intervention studies
Multiple studies showed that taurine supplementation
reduces fecal fat excretion and improves the nutritional status
of CF patients, particularly in patients with severe steatorrhoea
[39–41]. However, the beneficial effect of taurine supplemen-
tation on fat absorption is not unequivocally demonstrated [42–
45]. Furthermore, the degree of fat absorption did not relate to
changes in the serum glycine/taurine ratio in CF children [45].
Altogether, the use of taurine supplementation remains
controversial and is not implemented in nutritional CF care.
3.3. Intestinal mucosal abnormalities
3.3.1. CF conditions
Several intestinal mucosal abnormalities are described in CF
patients. These abnormalities include accumulation of viscous
and sticky mucus, SIBO, ileal hypertrophy and villous atrophy,
increased intestinal permeability and (chronic) inflammation of
the small intestine [46–53].
3.3.2. Relation with CFPFM
All the above mentioned factors may theoretically contribute
to fat malabsorption in CF patients, as they might impair
adequate translocation of fatty acids in(to) the enterocyte. In
addition, SIBO might impair micelle formation by the bacterial
deconjugation of bile salts [54]. However, no studies evaluated
the actual contribution of intestinal mucosal abnormalities to
CFPFM.
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The group of De Lisle et al. evaluated the effect of antibiotic
treatment on intestinal inflammation, mucus accumulation and
SIBO in CFTR™1Unc knockout mice [55]. CFTRtm1Unc
knockout mice display a phenotype of SIBO with a 400 fold
increase in small intestinal bacterial content compared to wild
type littermates [56]. Broad spectrum antibiotic treatment with
ciprofloxacine and metronidazole did not only reduce the
bacterial load in the small intestine, but also decreased intestinal
mucus accumulation and inflammation. More importantly,
3 weeks of treatment substantially improved the body weight
of these mice. The same effect on the bacterial load, intestinal
mucus accumulation, inflammation and body weight was
observed after laxative treatment [57]. It remains to be
elucidated whether the growth benefit was due to improved
fat absorption, reduced competition for nutrients by intestinal
bacteria or due to reduced intestinal inflammation. As O'Brien
et al. showed that a seven-day treatment with metronidazole
reduced fecal fat excretion in four CF patients [32], it is
reasonable to assume that the increased weight is due to
improved fat absorption Although the effect on fat absorption
was not assessed in either of these studies, the results suggest
that metronidazole might be a potential therapeutic option for
increasing fat absorption or nutritional status in CF patients.
One study evaluated the effect of probiotics on intestinal
inflammation in CF patients [49]. It has been suggested that
probiotics improve intestinal barrier function and modify the
immune response [58]. Bruzzese et al. reported that a four week
treatment with Lactobacillus rhamnosus GG, reduced fecal
calprotectin levels (marker for intestinal inflammation) in 8 out
of 10 treated CF patients [49]. The long term effect of probiotics
on intestinal inflammation was not evaluated, nor the effect on
fat absorption or nutritional status. We found only one mice
study which evaluated fat absorption after probiotics; lactoba-
cillus supplementation increased intestinal absorption of dietary
lipids in germ-free mice colonized with human baby flora [59].
Until now, the clinical value of probiotics and its relation with
fat absorption in CF patients are not clear.
3.4. Small intestinal transit time
3.4.1. CF conditions
No studies exclusively investigated small intestinal transit in
CF patients, but several groups have evaluated the oro-cecal
transit time (OCTT) [23]. The lactulose/hydrogen breath test
was most commonly applied to for determination of the OCTT.
Eighty five percent of CF patients had a prolonged OCTT (at
least +50%) in the fasted state [60,61]. Another method to
evaluate intestinal activity is by measuring the intestinal muscle
activity during the inter-digestive state, also known as the
migrating motor complex. The migrating motor complex
indirectly reflects the ability to transit food through the intestine.
Hallberg et al. showed that duodenal motility during fasting was
normal in 8 out of 10 CF patients [22]. This contradiction with
transit studies underlines the necessity to evaluate small
intestinal transit in CF patients. Especially, since intestinal
smooth muscle activity shows an erratic pattern and isunresponsive to cholinergic stimulation in CFTR™1Unc knock-
out mice [62]. It has been repeatedly shown, that these mice
have a slower small intestinal transit time in comparison to wild
type littermates on the same diet [57,64].
3.4.2. Relation with CFPFM
Fat absorption partly depends on the time fat is in contact
with the absorptive epithelium of the intestine. A classical
thought is that during fat malabsorption the intestine prolongs
the intestinal transit time (as a compensatory mechanism), in
order to enhance its ability to absorb fat; a phenomenon also
known as the ‘ileal brake’ [63]. It is reasonable to assume that
this compensatory mechanism also occurs in CFPFM as
intestinal transit time is prolonged in CF. However, prolonged
intestinal transit time is also a risk factor for the occurrence of
SIBO in CF conditions [8]. Therefore, one might ask, if
prolonged intestinal transit time might actually induce or
worsen CFPFM. The relation between intestinal transit time and
CFPFM is not yet evaluated.
3.4.3. Intervention studies
The research group of De Lisle et al. performed several
(intervention) studies on gastro-intestinal transit in CFTR™1Unc
knockout mice [57,62,64]. Oral laxative treatment improved
circular smooth muscle function in the small intestine and
normalized intestinal transit time [62]. Moreover, as earlier
described, laxative treatment reduced intestinal mucus accu-
mulation, eradicated overgrowth of bacteria in the small
intestine and improved body weight [57]. Unfortunately, fat
absorption was not evaluated in these studies. It is tempting to
speculate that laxative treatment may also improve the
nutritional status in CF patients, but before recommendations
could be made, more clinical data are needed.
3.5. Essential fatty acid deficiency
3.5.1. CF conditions
Despite high fat diets and PERT, CF patients can still have a
deficiency in essential fatty acids (EFA) [14]. In general, many
CF patients have subnormal levels of serum and tissue linoleic
acid (LA) and cervonic acid (DHA), often with increased levels
of arachidonic acid (AA) [14,65,66]. The reduction in EFA
levels is, apart from fat malabsorption, due to many other CF-
related factors. The exact mechanism behind the alterations in
EFA's still requires further exploration, but increased lipid
turnover in cellular membranes and increased oxidation of EFA's
are considered to play the most prominent role [14,67–70]. The
prevalence of EFA deficiency in CF patients strongly depends on
which biochemical marker is applied as a diagnostic criterion.
Magbool et al. recently demonstrated that the LA status in serum
phospholipids is more relevant than the triene/tetraene ratio
as a clinical indicator for EFA deficiency in CF patients [71].
When serum LA values are applied as a diagnostic criterion
for EFA-deficiency, around 40% of pediatric CF patients are
classified as EFA deficient [71]. The literature is not
consistent on the occurrence of EFA deficiency in CF
mice. Werner et al. reported that the LA and DHA contents
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knock-out mice and homozygous delta F508 mice [72], while
Freedman et al. reported decreased levels of DHA in the
ileum of CFTR™1Unc knock-out mice [73].
3.5.2. Relation with CFPFM
In relation to fat malabsorption, the EFA content in the
intestine is very important. EFA's provide fluidity and
flexibility to a cell membrane and play an important role in
the maintenance of cell membrane functionality of the
enterocyte. EFA deficiency in itself can cause fat malabsorption
by affecting the absorption capacity of the intestine [74]. Apart
from reduced LA and DHA levels, increased levels of AA in the
CF intestine could also (indirectly) affect fat absorption, by
contributing to intestinal inflammation, mucus secretion and
intestinal smooth muscle relaxation [79]. It has been shown that
EFA deficiency affects both the intra-luminal and intra-cellular
process of fat absorption, as exemplified in (non-CF) animal
models [69]. While the degree of EFA deficiency in CF patients
is generally mild, we cannot exclude the possibility that it might
interact with fat absorption. Especially since serum EFA levels
do not necessarily correlate with EFA levels in the intestine
[75,76]. Ex vivo experiments on intestinal biopsies from CF
patients indicated that abnormal intracellular lipid processing
occurs in the enterocyte [75]. A low incorporation of [
14
C]
palmitic acid in triglycerides was found in cultures of duodenal
biopsies after 18 h of incubation. The secretion of triglyceride-
rich chylomicrons was reduced in comparison to intestinal
biopsies from healthy controls [75]. Whether this impaired lipid
transport is due to EFA deficiency, to aberrant CFTR itself or to
a complex relation between the two, requires further investiga-Table 1
Factors that are suggested to contribute to fat malabsorption in cystic fibrosis (CF).
and CF mice and, interventional studies that evaluated fat absorption and/or nutrition
mice are mainly based on studies in CFTR knockout mice. References are described
cervonic acid. AA: arachidonic acid.
CF patients CF mice
(primarily CFTR knockout mic
Gastro-intestinal pH Duodenum: ↓ Duodenum: minor ↓
Jejunum: ↓ or ↔ Jejunum: not known
Ileum: ↔ Ileum: not known
Intraluminal bile salts Fecal bile salt excretion: ↑ Fecal bile salt excretion: ↑
Glycine/taurine ratio: ↑ Altered bile salt composition
Altered bile salt
composition
Intestinal wall
abnormalities
SIBO (~40%) SIBO
Intestinal mucus
accumulation
Intestinal mucus accumulation
Intestinal inflammation Intestinal inflammation
Intestinal permeability Intestinal permeability
Small intestinal transit
time
Not known Prolonged
Essential fatty acid
deficiency
Serum/tissue LA and
DHA: ↓ or ↔
Serum/tissue LA and DHA: ↓ or
Serum/tissue AA: ↑ or ↔
Serum/tissue AA: ↑ or ↔tion [77,78]. To what extent reduced intestinal EFA levels in CF
patients interfere with the actual percent absorption of dietary
fat intake is unknown. An association has been described
between the degree of EFA deficiency and the nutritional status
of CF patients [80], but EFA deficiency can also be present in
well nourished CF patients [81]. Thus, the clinical relevance of
the reduced EFA levels in CF patients on fat malabsorption
remains to be determined.
3.5.3. Intervention studies
Despite the abundance of (intervention) studies [66,82–85],
no study determined the effect of EFA supplementation on
CFPFM. Improved DHA levels in duodenal mucosa of CF
patients after 70 mg of DHA/kg body weight for 6 weeks has
been reported [66], but whether this improved fat absorption or
nutritional status was not described. Reviews on omega 3 fatty
acid supplementation or DHA supplementation alone, conclude
that there is still insufficient evidence for the therapeutic effect
of omega 3 fatty acids to recommend the routine use in CF
patients [82,85]. Other studies showed that energy supplements
rich in LA improved the body weight in CF patients, but it is
hard to differentiate between the effects of LA from that of a
high energy intake [83,84]. Accordingly, we do not recommend
the routine use of EFA supplements in CF for reasons to
enhance fat absorption, but it could be considered to improve
nutritional status in individual cases.
4. Summary, clinical implications and future perspectives
Several factors have been proposed to contribute to CFPFM
(Table 1). Based on the available data we consider it not likelyTable presents an overview of the described alterations observed in CF patients
al status. ↔: not affected, ↑: increased, ↓: decreased. The described data on CF
in the text. SIBO: small intestinal bacterial overgrowth. LA: linoleic acid. DHA:
e)
Treatment effect CF patients
(on fat absorption and weight)
Treatment effect CF mice
(on fat absorption and weight)
Bicarbonate enteric coated pancreatic
enzymes:
fat absorption: ↔ or minor ↑
weight: not known
Acid suppressant drugs:
triglyceride uptake: ↑
fatty acid uptake: ↑
weight: not known
Acid suppressant drugs:
fat absorption: ↔ or ↑
weight: ↔
Taurine supplementation:
fat absorption: ↔ or minor ↑
weight: ↔ or minor ↑
No interventional studies
No interventional studies Antibiotic treatment:
fat absorption: not known
weight: ↑
No interventional studies Laxative treatment:
fat absorption: not known
weight: ↑
↔ Energy supplements with LA:
fat absorption: not known
weight: ↑
No interventional studies
157M. Wouthuyzen-Bakker et al. / Journal of Cystic Fibrosis 10 (2011) 150–158that bile salt alterations do contribute to CFPFM. The
quantitative contribution of intestinal mucosal abnormalities,
small intestinal transit time and EFA deficiency to CFPFM
remains to be determined. Based on the findings in CF mouse
models, CF patients with signs of small bacterial overgrowth
might benefit from treatment with broad-spectrum antibiotics.
Antibiotic treatment should preferably be evaluated with
changes in nutritional status or fat absorption, using three day
fat balances. However, we should realize that three day fat
balances show high intra-individual variability, which exem-
plifies the need for novel methodologies to assess fat absorption
in CF patients. So far, the influence of reduced duodenal pH
levels seems most convincingly demonstrated to play a role in
CFPFM. Although not necessarily beneficial in all CF patients,
a trial of acid suppressive drugs might be helpful to optimize fat
absorption in individual cases.
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